Abstract: There is provided an ester compound represented by the formula I: ##STR1## wherein R.sub.1 is a methyl group or a hydrogen atom; R.sub.2 is a C.sub.1-6 haloalkyl group; and R.sub.3 is a pyrethroid acid residue, an agent for controlling noxious organisms containing the same as active ingredient and an intermediate for producing the same.

Abstract: Compounds of formula (I), and salts and prodrugs thereof wherein X, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.7 and R.sup.8 are defined herein, are tachykinin receptor antagonists.

Abstract: A composition for improving the anti-microbial activity of mammalian iodophor teat dips is disclosed, which includes an iodophor concentrate an organic acid buffer having an antimicrobial acid within the pKa range of from approximately 2.0 to 6.0, preferably within the pKa range of from approximately 3.0 to 5.0. Antimicrobial acids for use as the organic acid buffer include lactic acid, malic acid, mandelic acid, formic acid, glycolic acid, benzoic acid and combinations thereof.

Abstract: A method of obtaining optically active anhydrous phenylalanine crystals from an aqueous solution containing optically active phenylalanine, which involves crystallizing and precipitating optically active phenylalanine from an optically active phenylalanine super-saturated solution at a temperature, T, wherein the super-saturated solution is required to have an osmotic pressure .pi. (mOsm/kg.H.sub.2 O) which is related to said temperature T in accordance with the following formula (I):.pi..gtoreq.10,500-450T+4.4T.sup.2 (I),wherein the method provides anhydrous crystals having excellent handleability.

Abstract: Compounds of Formula 1 bind opioid receptors: which binds to the opioid receptor: ##STR1##

Abstract: This invention relates to compounds which are N-oxides and derivatives of chlorambucil and which, under certain conditions, (1) are stable in hypoxic and oxic cells, (2) are toxic in cells having varying degrees of hypoxia, and (3) show little toxicity to oxic cells. These compounds have the general formula set out below and are used to treat tumorous cells: ##STR1## wherein R is an alkyl, aryl, or derivatives thereof, such as CH.sub.3 OCH.sub.2 CH.sub.2 --; CH.sub.3 CH.sub.2 OCH.sub.2 CH.sub.2 --; C.sub.6 H.sub.5 OCH.sub.2 CH.sub.2 --; C.sub.6 H.sub.5 CH.sub.2 --; CH.sub.3 (CH.sub.2).sub.3 OCH.sub.2 CH.sub.

Abstract: The present invention is directed to a method for preventing or reducing ischemia following injury, such as reperfusion injury following ischemia, cellular damage associated with ischemic episodes, such as infarctions or traumatic injuries, and thus to prevent or reduce the consequent progressive necrosis of tissue associated with such ischemia. This effect is achieved by administering DHEA or DHEA derivatives to a patient as soon as possible after the injury. The present invention is further directed to methods for preventing or reducing bacterial translocation or adult respiratory distress syndrome in a patient. Similarly, bacterial translocation and adult respiratory distress syndrome are prevented or reduced by administering DHEA or DHEA derivatives to a patient. Suitable derivatives of DHEA include, among others, 16.alpha.

Abstract: Disclosed is an acetyltransferase activity measuring agent which contains an arylamine derivative. As the arylamine derivative, sodium p-aminohippurate can be used preferably. Use of the acetyltransferase activity measuring agent of this invention permits a simple and safe diagnosis of the progress of the pathema of nephritis, which is accompanied by a mesangial proliferative lesion, or renal insufficiency. Furthermore, the scattering of measured values is small, thereby assuring an accurate diagnosis.

Abstract: Alkyl derivatives of trazodone endowed with pharmacological activity, pharmaceutical compositions containing them, process for preparing them and intermediate compounds useful in their preparation.

Abstract: 3,7-disubstituted indole derivatives of formula I ##STR1## wherein R.sub.1, R.sub.2, n, X, Y and Z are as defined in the description, are useful for the treatment of psychiatric disorders.

Abstract: The present invention relates to a novel process for the preparation of ethyl 3S-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentyno ate and pharmaceutically acceptable acid addition salt thereof which comprises treating (trimethylsilyl)acetylene sequentially with n-butyllithium and 4-formylmorpholine followed by acid hydrolysis to give 3-(trimethylsilyl)-2-propynal; treating 3-(trimethylsilyl)-2-propynal with lithium bis(trimethylsilyl)amide to give in situ N,3-bis(trimethylsilyl)-2-propyn-1-imine; condensation of N,3-bis(trimethylsilyl)-2-propyn-1-imine with lithium t-butyl acetate to give (.+-.)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate; treating (.+-.)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate- with p-toluenesulfonic acid to give (.+-.)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate, mono p-toluenesulfonic acid salt, treatment of resulting salt with ethanol in the presence of p-toluenesulfonic acid to give (.+-.

Abstract: Compounds of Formula 1 bind to the opioid receptors: ##STR1## wherein R.sub.1 is a group of the formula ##STR2## where W is --(CH.sub.2).sub.a -- (where a is 0, 1, or 2), --O--, --NH--, --S--, --SO--, or --SO.sub.2 --, and Ar is phenyl, phenyl-alkyl, phenyl substituted with 1-3 halo, nitro, lower alkyl, hydroxy, amino, alkylamino, dialkylamino, and/or hydroxy-lower alkyl groups, and n is 0, 1, 2, 3, or 4;R.sub.2 and R.sub.3 are each independently H, lower alkyl, or ##STR3## where X is H, OH, lower alkyl, or lower alkoxy, and p is 0, 1, 2, or 3; R.sub.4 is ##STR4## where m is 0, 1, 2, or 3, and R is 1-3 halo, nitro, lower alkyl, hydroxy, amino, alkylamino, dialkylamino, and/or hydroxy-lower alkyl groups;R.sub.5 is cycloalkyl, bicycloalkyl, or tricycloalkyl; andR.sub.6, R.sub.7, R.sub.8, and R.sub.9 are each independently H or lower alkyl.

Abstract: The reaction between methanol, carbon monoxide and oxygen for preparing dimethyl carbonate, in the presence of cuprous chloride as the catalyst, is carried out in a special reactor constituted by two parallel, vertical tubes, at the base of one of which the fresh gas and the recycle gas are fed; the reaction products are separated by partially condensing the recirculate vapors.

Abstract: A method for handling and stabilizing a (2-alkyl)-acryloyl isocyanate represented by the formula (1) ##STR1## is disclosed, which comprises the steps of: reacting an azomethine compound represented by formula (2) ##STR2## with the (2-alkyl)-acryloyl isocyanate of formula (1) to obtain the reaction product of formula (3) ##STR3## and dissolving said reaction product into a solvent to regenerate the (2-alkyl)-acryloyl isocyanate of formula (1); the identity of said solvent and R-groups being defined herein.

Abstract: A process for quickly and reproducibly obtaining .alpha.-L-aspartyl-L-phenylalanine methyl ester with controlled water content is disclosed. Wet crystals of .alpha.-L-aspartyl-L-phenylalanine methyl ester obtained by crystallization are subjected to a drying step to adjust the water content to not more than 5 wt %, and subsequently a gas adjusted to a temperature of 20-80.degree. C. and relative humidity of 20-90 RH % is contacted with the dried crystals to control water content.

Abstract: Addition of a reaction mixture obtained by the mineral acid hydrolysis of at least one side flow generated from the production of .alpha.-L-aspartyl-L-phenylalanine methyl ester to a crystallization slurry containing L-phenylalanine while maintaining the pH of the slurry at 3-8 by adding aqueous alkali affords crystallized L-phenylalanine having a low water content in a high yield.

Abstract: The cyclohexadiene derivatives are prepared by reaction of cyclohexanones with amines and subsequent dehydration. The compounds are suitable as active compounds in medicaments on account of their property of being selective modulators of calcium channel-dependent potassium channels.

Abstract: Disclosed herein is a process for producing a (2S,5S)-2,5-diamino-1,6-diphenyl-3-hexanone derivative represented by the formula (1): ##STR1## wherein R.sup.1 means a lower alkylcarbonyl group, a halogen-substituted lower alkylcarbonyl group, an arylcarbonyl group or a lower alkoxycarbonyl group, and R.sup.2 and R.sup.3 are identical with or different from each other and denote individually an aryl group or an alkoxy-substituted aryl group, which comprises subjecting a (2S)-2,5-diamino-1,6-diphenyl-4-hexen-3-one derivative represented by the formula (2): ##STR2## wherein R.sup.1, R.sup.2 and R.sup.3 have the same meaning as defined above, to a hydrogenation reaction in the presence of a transition metal-containing catalyst.

Abstract: This invention relates to levogyral isomers of alkylammonium (amino-3 phenyl)-1 ethanesulphonate derivatives of formula (I) in which R+ denotes a tetraalkylammonium or trialkylphenylalkylammonium residue. The invention also concerns the preparation and use of said derivatives.

Abstract: This invention relates to a retinoid mpound of formula I ##STR1## in which Y is --CO--NH--, --CR.sup.2 .dbd.CR.sup.3 --, --CO--O--, --O--CO--, --C(.dbd.S)--NH--, --C.tbd.C--, --O--CH.sub.2 --, --CH.sub.2 --O--, or --CH.sub.2 --CH.sub.2 --;A is --(CH.sub.2).sub.t -- or a bond;Q is phenyl optionally substituted with one to three same or different C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen, or --CO.sub.2 R.sup.4 ;R.sup.1 is --CO.sub.2 Z, --CONHR.sup.5, C.sub.1-6 alkyl, --CH.sub.2 OH, or --CHO;R.sup.2, R.sup.3, R.sup.4, R.sup.5, and Z are independently hydrogen or C.sub.1-6 alkyl;t is one to six.